Global Custom Market Research Reports Provider Company

phone

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 71
  • Category: Pharmaceuticals
  • Country: Global

20%

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018

Summary

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 10 molecules. The latest report Integrin Alpha 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Integrin Alpha 4 is a protein encoded by ITGA4. Integrins alpha-4 (VLA-4) subunit associates with a beta 1 or beta-7 subunit to form an integrin that plays a role in cell motility and migration. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohns disease and inflammatory bowel disease. They are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3, 3 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Central Nervous System, Immunology, Infectious Disease, Oncology, Cardiovascular, Genetic Disorders, Ophthalmology and Respiratory which include indications Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Age Related Macular Degeneration, Asthma, Autoimmune Disorders, Celiac Disease, Crohns Disease (Regional Enteritis), Duchenne Muscular Dystrophy, Epilepsy, Genital Warts (Condylomata Acuminata), Human Immunodeficiency Virus (HIV) Infections (AIDS), Multiple Sclerosis, Paraneoplastic Syndrome, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Ventricular Septal Defect.

Furthermore, this report also reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Antisense Therapeutics Ltd
Biogen Inc
BioMAS Ltd
Daiichi Sankyo Co Ltd
EA Pharma Co Ltd
Immunwork Inc
Morphic Therapeutic Inc
Takeda Pharmaceutical Co Ltd
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
AS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATL-1102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carotegrast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ET-3764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
natalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TE-5232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2018: Takeda Obtains New Drug Application Approval for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis in Japan
Jun 05, 2018: Analysis of real-world safety data shows gut-selective ENTYVIO (vedolizumab) had fewer serious infections and adverse events than those on systemic TNFa-antagonist therapy in ulcerative colitis and Crohns disease patients
Jun 03, 2018: Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohns Disease
May 15, 2018: Bio-Rad Introduces Anti-Vedolizumab Antibodies
Feb 28, 2018: Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy
Feb 16, 2018: Entyvio (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohns Disease Patients in Comparative Effectiveness Real-World Data Analysis
Feb 07, 2018: Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Feb 06, 2018: Takeda Announces Publication of Study Utilizing State-of-the-Art Modeling to Better Understand Optimal Treatment Positioning for Patients with Ulcerative Colitis
Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update
Nov 09, 2017: New Post-Hoc Analysis Evaluating Deep Remission with Entyvio (vedolizumab) in Patients with Moderately to Severely Active Ulcerative Colitis Recognized as "Poster of Distinction" at AIBD 2017 Annual Conferenc
Nov 01, 2017: Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohns Disease
Oct 30, 2017: ATL1102 Black Hole MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting
Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update
Oct 16, 2017: New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohns Disease Patients Taking Entyvio (vedolizumab), Particularly in Biologic-Nave Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Antisense Therapeutics Ltd, H2 2018
Pipeline by Biogen Inc, H2 2018
Pipeline by BioMAS Ltd, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by EA Pharma Co Ltd, H2 2018
Pipeline by Immunwork Inc, H2 2018
Pipeline by Morphic Therapeutic Inc, H2 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H2 2018 According to the recently published report Integrin Beta 3 - Pipeline Review, H2 2018; Integrin

View Report

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2018 Integrin Alpha 4 (CD49 Antigen Like Family Member D

View Report

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Pipeline Review, H1 2018 Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports